Lonestar Algisyl-LVR, page-16

http://www.marketwatch.com/story/su...on-options-hf-eu-post-market-study-2014-12-01

EDEN PRAIRIE, Minn., Dec 01, 2014 (GLOBE NEWSWIRE via COMTEX) --
Sunshine Heart, Inc. SSH, -0.75% announced today that the Company's initial Austrian site for the OPTIONS-HF study has implanted its first patient with the C-Pulse System for moderate to severe heart failure. Prof. Dr. Herwig Antretter of the University of Innsbruck performed the operation, which took place on November 11th, 2014. A 92 minute surgical implantation procedure was successfully completed and the patient was discharged from the hospital 7 days post-surgery. This milestone marks the eleventh implantation of the C-Pulse System across fourteen activated EU centers participating in the OPTIONS HF post-market surveillance clinical study.
"The C-pulse system is an ideal addition for patients in the treatment of NYHA III and ambulatory IV stage heart failure," said Prof. Dr. Antretter. "It is easy to implant the device, doesn´t need a heart lung machine, and allows for quick patient recovery. Our patient was extubated in the operating room, stayed just a couple of hours in the ICU, and was then transferred to a normal ward. We discharged him after only one week."